S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

INDP Indaptus Therapeutics Inc

0.94

-0.01 (-1.05%)

Last Updated: 02:40:12

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Indaptus Therapeutics Charts.

Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Indaptus Therapeutics Charts.

Indaptus Therapeutics Inc News

Form D - Notice of Exempt Offering of Securities
Thursday 23 January 2025 (5 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 15 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Tuesday 14 January 2025 (2 weeks ago) • GlobeNewswire Inc.

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
Thursday 9 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Form S-1 - General form for registration of securities under the Securities Act of 1933
Tuesday 24 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Saturday 23 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Saturday 23 November 2024 (2 months ago) • Edgar (US Regulatory)

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
Saturday 23 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 13 November 2024 (3 months ago) • Edgar (US Regulatory)

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Wednesday 13 November 2024 (3 months ago) • GlobeNewswire Inc.

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Tuesday 12 November 2024 (3 months ago) • GlobeNewswire Inc.

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Friday 8 November 2024 (3 months ago) • GlobeNewswire Inc.

More Indaptus Therapeutics Inc News Articles

S&P ASX 300 Metals and M...

Gold vs US Dollar

Commonwealth Bank Of Aus...

Woodside Petroleum

National Australia Bank

Westpac Banking

Sterling vs AUD

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions